• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    2/27/25 4:15:00 PM ET
    $ANAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANAB alert in real time by email
    • Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months
    • Full clinical and translational data for rosnilimab in RA in Q2 2025
    • Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025
    • Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator
    • Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist
    • Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027

    SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.

    "Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials. In Q2 2025, we will report full clinical and translational data, further validating rosnilimab's transformative potential to restore immune homeostasis, not only in RA but also in other diseases like ulcerative colitis. We also are excited to report top-line Phase 2 data for rosnilimab in UC moved up to Q4 2025," said Daniel Faga, president and chief executive officer of Anaptys. "Additionally, Phase 1 development of both ANB033 and ANB101 is advancing as planned. With approximately $420 million of cash coming into 2025, we are well capitalized through year-end 2027, which does not include the significant potential residual royalties and milestones from our GSK financial collaboration."

    Updates on Asset Portfolio

    Rosnilimab (PD-1 depleter and agonist)

    • Announced subcutaneously administered rosnilimab, including two once-monthly doses, achieved positive results in 424-patient Phase 2b RA trial and highest-ever reported clinical disease activity index (CDAI) low disease activity (LDA) response over 6 months
      • Key results for the trial were –
        • Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS28-CRP score across all three rosnilimab doses vs. placebo
        • Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA
        • Demonstrated highest-ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA
        • 69% (220/318) of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28
        • Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs and reduction of CRP across all doses
        • Rosnilimab was safe and well tolerated with similar adverse event rates vs. placebo
        • Full press release can be found here
      • Full clinical and translational data anticipated in Q2 2025
    • Enrollment ongoing for global Phase 2 trial in moderate-to-severe UC
      • 132-patient trial assessing two dose levels of subcutaneously administered rosnilimab vs. placebo (randomized 1:1:1)
        • Primary statistical analysis at Week 12 on well-established endpoints, including the primary endpoint of change from baseline in modified Mayo score (mMS) and supportive secondary endpoints of clinical response on mMS, clinical remission on mMS and endoscopic remission
        • All patients in all three study arms treat-through to Week 24 and remain blinded to treatment arm. Placebo-treated patients who achieved clinical response on partial modified Mayo score (pmMS) at Week 12 remain on placebo, while placebo-treated patients who are non-responders are crossed over to the high-dose rosnilimab treatment arm
        • Patients who are in clinical response on pmMS at Week 24 are eligible for an additional 26-weeks (50 weeks of total treatment), blinded treatment extension period (TEP)
      • Top-line data anticipated in Q4 2025
    • Presented preclinical data in Q4 2024 and Q1 2025 (available here) evaluating –
      • The PD-1 depletion and agonism mechanisms of rosnilimab in vitro with UC patient-derived PBMCs and a mouse model of colitis at the 2024 United European Gastroenterology Week (UEGW)
      • Inflammatory pathway gene expression in PD-1+ conventional and regulatory T cells in human UC tissue and rosnilimab's effects in a mouse model of colitis at the European Crohn's and Colitis Organisation (ECCO) Congress
      • Synovial levels of PD-1 and the correlation with disease activity in RA at American College of Rheumatology (ACR) Convergence

    ANB033 (CD122 antagonist)

    • Enrollment ongoing for Phase 1a trial in healthy volunteers
      • Phase 1b indication to be disclosed at a 2025 R&D event

    ANB101 (BDCA2 modulator)

    • Investigational new drug (IND) application accepted by FDA
    • Phase 1a trial to initiate in healthy volunteers in Q1 2025

    Imsidolimab (IL-36 antagonist)

    • Announced an exclusive global out-license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab (IL-36R antagonist)
      • Anaptys received $15 million, comprised of a $10 million upfront payment and $5 million for existing drug supply
      • Anaptys eligible to receive up to $35 million for future regulatory approvals and sales milestones in addition to a 10% royalty on global net sales

    GSK Immuno-Oncology Financial Collaboration

    • GSK announced strong commercial performance for Jemperli ($190 million in Q4 2024 sales) with >100% year-over-year growth
    • GSK anticipates top-line data in H1 2025 from COSTAR Lung Phase 3 trial comparing cobolimab, a TIM-3 antagonist, plus dostarlimab, a PD-1 antagonist, plus docetaxel to dostarlimab plus docetaxel and to docetaxel alone in patients with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy and platinum-based chemotherapy
    • GSK anticipates top-line data in 2026 from AZUR-1 pivotal Phase 2 trial of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
      • Jemperli received U.S. FDA Breakthrough Therapy Designation for this indication in December 2024

    Cash Runway

    • Cash and investments of $420.8 million as of Dec. 31, 2024, and reiterating cash runway through year-end 2027

    Fourth Quarter and Full Year 2024 Financial Results

    • Cash, cash equivalents and investments totaled $420.8 million as of December 31, 2024, compared to $417.9 million as of December 31, 2023, for an increase of $2.9 million due primarily to the $100 million underwritten registered direct offering completed in Q3 and $50.0 million received from the Sagard royalty monetization in Q2 offset by 2024 operating activities.
    • Collaboration revenue was $43.1 million and $91.3 million for the three and twelve months ended December 31, 2024, compared to $9.0 million and $17.2 million for the three and twelve months ended December 31, 2023. The increase in non-cash revenue in 2024 is due to $15.0 million and $25.0 million commercial milestones earned for annual Jemperli sales exceeding $250.0 million and $500.0 million during the year and increased royalties recognized for sales of Jemperli. For the year ended December 31, 2024, GSK reported $598.0 million in sales for Jemperli, a greater than 200% sales growth when compared to $175.6 million for the year ended December 31, 2023.
    • Research and development expenses were $42.6 million and $163.8 million for the three and twelve months ended December 31, 2024, compared to $33.5 million and $132.3 million for the three and twelve months ended December 31, 2023. The increase was due primarily to development costs for rosnilimab, ANB032, ANB033 and ANB101 offset by a decrease in development costs for imsidolimab. The R&D non-cash, stock-based compensation expense was $3.9 million and $14.8 million for the three and twelve months ended December 31, 2024 as compared to $2.5 million and $10.2 million in the same period in 2023.
    • General and administrative expenses were $10.2 million and $42.4 million for the three and twelve months ended December 31, 2024, compared to $10.3 million and $41.9 million for the three and twelve months ended December 31, 2023. The G&A non-cash, stock-based compensation expense was $4.3 million and $19.2 million for the three and twelve months ended December 31, 2024 as compared to $5.6 million and $23.0 million in the same period in 2023.
    • Net loss was $21.8 million and $145.2 million for the three and twelve months ended December 31, 2024, or a net loss per share of $0.72 and $5.12, compared to a net loss of $42.2 million and $163.6 million for the three and twelve months ended December 31, 2023, or a net loss per share of $1.59 and $6.08.

    About Anaptys

    Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company's clinical trials, including rosnilimab's full Phase 2b clinical trial data in rheumatoid arthritis and top-line Phase 2 clinical trial data in ulcerative colitis; whether current trends in full clinical data in rheumatoid arthritis will be maintained once complete data becomes available; whether positive clinical trial results in rosnilimab's Phase 2b clinical trial in rheumatoid arthritis increases the likelihood of getting positive results from rosnilimab's Phase 2 clinical trial in ulcerative colitis; timing of initiation of ANB101's Phase 1 clinical trial; the potential to receive any royalties or milestone payments from the Vanda Pharmaceuticals license agreement; the potential to receive any additional milestones and royalties from the GSK collaboration; and the Company's projected cash runway. Statements including words such as "plan," "continue," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

    Contact:

    Nick Montemarano

    Executive Director, Investor Relations

    858.732.0178

    [email protected]

     
    AnaptysBio, Inc.

    Consolidated Balance Sheets

    (in thousands, except par value data)
     
     December 31, 2024 December 31, 2023
     
    ASSETS
    Current assets:   
    Cash and cash equivalents$123,080  $35,965 
    Receivables from collaborative partners 40,765   6,851 
    Short-term investments 262,293   354,939 
    Prepaid expenses and other current assets 5,738   9,080 
    Total current assets 431,876   406,835 
    Property and equipment, net 1,849   2,098 
    Operating lease right-of-use assets 14,383   16,174 
    Long-term investments 35,470   27,026 
    Other long-term assets 256   256 
    Total assets$483,834  $452,389 
    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:   
    Accounts payable$4,002  $4,698 
    Accrued expenses 39,501   30,967 
    Current portion of operating lease liability 1,925   1,777 
    Total current liabilities 45,428   37,442 
    Liability related to sale of future royalties 353,426   310,807 
    Operating lease liability, net of current portion 14,112   16,037 
    Stockholders' equity:   
    Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2024 and December 31, 2023, respectively —   — 
    Common stock, $0.001 par value, 500,000 shares authorized, 30,473 shares and 26,597 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively 30   27 
    Additional paid in capital 829,860   702,969 
    Accumulated other comprehensive gain (loss) 305   (797)
    Accumulated deficit (759,327)  (614,096)
    Total stockholders' equity 70,868   88,103 
    Total liabilities and stockholders' equity$483,834  $452,389 
     



     
    AnaptysBio, Inc.

    Consolidated Statements of Operations and Comprehensive Loss

    (in thousands, except per share data)
     
     Three Months Ended

    December 31,
     Year Ended

    December 31,
      2024   2023   2024   2023 
    Collaboration revenue$43,113  $9,005  $91,280  $17,157 
    Operating expenses:       
    Research and development 42,589   33,525   163,840   132,283 
    General and administrative 10,194   10,276   42,389   41,946 
    Acquired in-process research and development —   7,339   —   7,339 
    Total operating expenses 52,783   51,140   206,229   181,568 
    Loss from operations (9,670)  (42,135)  (114,949)  (164,411)
    Other (expense) income, net:       
    Interest income 5,263   4,880   19,794   18,873 
    Non-cash interest expense for the sale of future royalties (17,404)  (4,958)  (50,087)  (18,083)
    Other income (expense), net 21   (2)  14   (2)
    Total other (expense) income, net (12,120)  (80)  (30,279)  788 
    Loss before income taxes (21,790)  (42,215)  (145,228)  (163,623)
    Benefit (Provision) for income taxes 6   4   (3)  4 
    Net loss (21,784)  (42,211)  (145,231)  (163,619)
    Other comprehensive income (loss):       
    Unrealized (loss) gain on available for sale securities (454)  1,553   1,102   4,449 
    Comprehensive loss$(22,238) $(40,658) $(144,129) $(159,170)
    Net loss per common share:       
    Basic and diluted$(0.72) $(1.59) $(5.12) $(6.08)
    Weighted-average number of shares outstanding:       
    Basic and diluted 30,448   26,586   28,382   26,924 


    Primary Logo

    Get the next $ANAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANAB

    DatePrice TargetRatingAnalyst
    2/4/2025$25.00Outperform
    Wolfe Research
    12/11/2024$52.00 → $19.00Buy → Neutral
    H.C. Wainwright
    12/2/2024Buy → Neutral
    BTIG Research
    7/22/2024$55.00Buy
    H.C. Wainwright
    7/19/2024$29.00 → $69.00Neutral → Overweight
    JP Morgan
    4/16/2024$47.00Outperform
    Leerink Partners
    4/11/2024$56.00Overweight
    Wells Fargo
    3/12/2024$20.00 → $34.00Neutral → Outperform
    Wedbush
    More analyst ratings

    $ANAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

      Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway through year-end 2027 SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, tod

      5/5/25 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Anaptys Announces Stock Repurchase Plan

      SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company's outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previ

      3/24/25 9:15:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ecor1 Capital, Llc bought $1,099,642 worth of shares (85,098 units at $12.92) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/2/25 6:17:02 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Ecor1 Capital, Llc bought $9,999,978 worth of shares (273,972 units at $36.50) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      8/16/24 12:04:31 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    SEC Filings

    See more
    • SEC Form 10-Q filed by AnaptysBio Inc.

      10-Q - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:19:46 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANAPTYSBIO, INC (0001370053) (Filer)

      5/5/25 4:17:51 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.

      SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      4/30/25 10:57:53 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on AnaptysBio with a new price target

      Wolfe Research initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $25.00

      2/4/25 6:58:43 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded AnaptysBio from Buy to Neutral and set a new price target of $19.00 from $52.00 previously

      12/11/24 12:23:14 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio downgraded by BTIG Research

      BTIG Research downgraded AnaptysBio from Buy to Neutral

      12/2/24 6:53:00 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 4:00:05 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AnaptysBio Inc.

      SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)

      11/14/24 9:24:47 AM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by AnaptysBio Inc.

      SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)

      8/16/24 12:07:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANAB
    Financials

    Live finance-specific insights

    See more

    $ANAB
    Leadership Updates

    Live Leadership Updates

    See more

    $ANAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

      Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b

      5/11/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

      After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a

      9/18/23 4:15:00 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. acquired $201,241 worth of shares (11,068 units at $18.18) (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      3/27/25 4:10:12 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. exercised 42,337 shares at a strike of $6.50, increasing direct ownership by 1,086% to 46,237 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/15/25 5:04:11 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Lizzul Paul F. covered exercise/tax liability with 6,597 shares and converted options into 16,700 shares, increasing direct ownership by 65% to 25,643 units (SEC Form 4)

      4 - ANAPTYSBIO, INC (0001370053) (Issuer)

      1/7/25 5:33:21 PM ET
      $ANAB
      Biotechnology: Pharmaceutical Preparations
      Health Care